IDYA · Company research
IDEAYA Biosciences, Inc. Common Stock (IDYA): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
14records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History - Yahoo! Finance Canada | IDEAYA Biosciences, Inc. (IDYA) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 9, 2026 | neutral | 0 | 0.6 |
| Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). - Stock Titan | Option exercises are part of a CEO's proposed share sale at IDEAYA (Nasdaq: IDYA). Stock Titan | View source ↗ | Stock Titan | Oct 6, 2026 | neutral | 0 | 0.6 |
| IDEAYA Biosciences (IDYA) Stock Looks Priced At A Premium Despite R And D Promotion - Simply Wall Street | IDEAYA Biosciences (IDYA) Stock Looks Priced At A Premium Despite R And D Promotion Simply Wall Street | View source ↗ | Simply Wall Street | Oct 1, 2026 | neutral | 0 | 0.6 |
| After five years as IDEAYA's chief scientist, Michael White becomes president of research and development. - Stock Titan | After five years as IDEAYA's chief scientist, Michael White becomes president of research and development. Stock Titan | View source ↗ | Stock Titan | Sep 28, 2026 | neutral | 0 | 0.6 |
| Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? - Yahoo Finance | Can IDEAYA Biosciences (IDYA) Turn Uncharted Oncology Territory Into Commercial Gold? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) - Seeking Alpha | Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform (IDYA) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 25, 2026 | neutral | 0 | 0.6 |
| IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup - ChartMill | IDEAYA Biosciences (NASDAQ:IDYA) Displays Perfect Technical Strength and Breakout Setup ChartMill | View source ↗ | ChartMill | Aug 10, 2026 | neutral | 0 | 0.6 |
| IDYA Forecast — Price Target — Prediction for 2027 - TradingView | IDYA Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire | IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire | View source ↗ | PR Newswire | Jun 8, 2026 | neutral | 0 | 0.6 |
| $IDYA stock is up 11% today. Here's what we see in our data. - Quiver Quantitative | $IDYA stock is up 11% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Jun 8, 2026 | neutral | 0 | 0.6 |
| Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? - Yahoo Finance | Is IDEAYA Biosciences, Inc. (IDYA) A Good Stock To Buy Now? Yahoo Finance | View source ↗ | Yahoo Finance | May 3, 2026 | neutral | 0 | 0.6 |
| Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? - Stocktwits | Why Is Ideaya Biosciences (IDYA) Stock Surging Over 20% Overnight? Stocktwits | View source ↗ | Stocktwits | Apr 13, 2026 | neutral | 0 | 0.6 |
| IDYA Stock Pops As New Cancer Trials Ignite Trader Focus - Timothy Sykes | IDYA Stock Pops As New Cancer Trials Ignite Trader Focus Timothy Sykes | View source ↗ | Timothy Sykes | Apr 10, 2026 | neutral | 0 | 0.6 |
| IDEAYA Biosciences, Inc. Common Stock (IDYA) Stock Price: Oct 8 Close $36.06 - Gotrade | IDEAYA Biosciences, Inc. Common Stock (IDYA) Stock Price: Oct 8 Close $36.06 Gotrade | View source ↗ | Gotrade | Feb 2, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.